Orthopediatrics CORP 10-Q quarterly reports

OrthoPediatrics Corp. announced its second quarter 2026 financial results, showing a 15% increase in net revenue to $70.5 million, but also reporting a net loss of $7.2 million.

OrthoPediatrics reports 13% revenue growth to $59.4 million for Q1 2026, driven by strong performance in trauma, deformity, and scoliosis product lines.

OrthoPediatrics Corp. reported a widened net loss in Q3 2025 despite revenue growth, driven by increased operating expenses, impairment charges, and restructuring costs.

OrthoPediatrics Corp. reported a 16% increase in net revenue for Q2 2025, reaching $61.1 million, but also saw its net loss widen to $7.1 million due to higher costs and restructuring expenses.

OrthoPediatrics Corp. announces a 17% increase in net revenue for the first quarter of 2025, driven by growth in trauma and deformity, scoliosis, and O&P bracing segments.

OrthoPediatrics Corp. saw a 37% increase in net revenue in the third quarter of 2024, driven by acquisitions and strong performance across its product lines.

OrthoPediatrics Corp. saw a significant increase in revenue during the second quarter of 2024, driven by acquisitions and strong performance across its product lines.

OrthoPediatrics Corp. saw a 41% increase in net revenue in the first quarter of 2024, driven by acquisitions and strong performance across its product lines.